Coumarins (including Hydrogenated) Patents (Class 514/457)
-
Publication number: 20110028420Abstract: A method is disclosed for treating and inducing the regression of established atherosclerotic plaques. A method is disclosed for treating asthma, including treatment of an ongoing asthma attack. In both cases, treatment with PARP inhibitors, such as the PARP inhibitor TIQ-A (Thieno[2,3-c]isoquinolin-5-one), can lead to regression of existing disease and symptoms.Type: ApplicationFiled: April 7, 2009Publication date: February 3, 2011Inventors: Hamid A. Boulares, Chetan P. Hans, Amarjit S. Naura
-
Publication number: 20110021621Abstract: The present invention relate to a drug for treating circulatory insufficiency containing a benzopyran derivative represented by the following general formula (I): and/or a physiologically acceptable salt thereof as an active ingredient, wherein R1 is an alkyl group having 1 to 10 carbon atoms, or an alkenyl group having 2 to 10 carbon atoms; and any one of R2, R3, R4 and R5 is a hydroxyl group, an alkoxy group, an alkenyloxy group, an alkoxy group substituted with a hydroxyl group, or an alkoxy group substituted with a carboxy group, and the others are hydrogen atoms.Type: ApplicationFiled: September 29, 2010Publication date: January 27, 2011Applicant: ACTIVUS PHARMA CO., LTD.Inventors: Hidetsugu Takagaki, Yasuo Aoki, Mitsuteru Ishiwara
-
Patent number: 7863322Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: GrantFiled: March 2, 2004Date of Patent: January 4, 2011Assignee: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim
-
Patent number: 7846966Abstract: The invention provides chroman compounds having formula 1 wherein R1 is (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl, and independently R1 has a cis-orientation in relation to the exocyclic phenyl group at the 2-position of the skeleton; R4 is H, Hal, CF3, OH or (1C-2C)alkyloxy; R2, R3, and R5 are independently H, Hal, CF3, (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl and prodrugs thereof for the manufacture of a medicine for estrogen-receptor related treatments.Type: GrantFiled: May 8, 2009Date of Patent: December 7, 2010Assignee: N.V. OrganonInventors: Gerrit Herman Veeneman, Neeltje Miranda Teerhuis
-
Publication number: 20100304966Abstract: Compounds of the formula I in which the substituents have the meaning given in the description, processes for preparing these compounds, compositions comprising them and their use for controlling harmful fungi.Type: ApplicationFiled: October 9, 2008Publication date: December 2, 2010Applicant: BASF SEInventors: Joachim Rheinheimer, Barbara Nave, Doris Kremzow, Stefan Redlich, Christian Pilger, Claudia Rosenbaum, Wassilios Grammenos
-
Publication number: 20100305070Abstract: The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described herein in treating cancer.Type: ApplicationFiled: April 30, 2010Publication date: December 2, 2010Applicant: The University Court of the University of DundeeInventors: Steven Albert Everett, Saraj Ulhaq
-
Patent number: 7842721Abstract: A pharmaceutical composition having a cytotoxic effect to a cancer cell is provided. The pharmaceutical composition includes a flavonoid compound having a formula as wherein B ring is a 4-oxo-cyclohexa-2,5-dienyl group, and any one of R1-R12 is one selected from a group consisting of hydrogen group, hydroxyl group, C1-C20 alkyl group, C1-C20 ether group, C1-C20 ester group, carboxyl group, halogen and sugar. The flavonoid compound is obtained from a chemical method being one of a total synthesis method and a semi-synthesis method.Type: GrantFiled: August 24, 2007Date of Patent: November 30, 2010Assignee: Kaohsiung Medical UniversityInventors: An-Shen Lin, Yang-Chang Wu, Kuo-Hsiung Lee, Fang-Rong Chang
-
Publication number: 20100267819Abstract: The invention relates to a pharmaceutical composition for diabetic nephropathy and its preparation, and the application in preparing of medicine for diabetic nephropathy. The pharmaceutical composition is made up of at least one of 7-hydroxycoumarin and 7-hydroxy-6-methoxycoumarin as active ingredient, and the weight percentage of active ingredient is 0.1-99.5%. Moreover, the pharmaceutical composition is mainly used for the prevention and cure of diabetic nephropathy. For the abundant material, remarkable effect on prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients.Type: ApplicationFiled: June 25, 2010Publication date: October 21, 2010Applicant: Guangzhou Consun Medicine R&D MedicineInventors: QUAN ZHU, Xinghua Shi, Dan Tang, Zhaoguang Zheng, Bao He, Tingting Duan, Fei Gu, Huiquan Cheng, Xiaoling Huang, Yanxia Huang, Rushang Wang
-
Publication number: 20100267653Abstract: The invention provides coumarin compounds, in particular glycosidic coumarin compounds, useful in the treatment of dermatophyte fungal infections.Type: ApplicationFiled: June 5, 2007Publication date: October 21, 2010Inventor: Colin Stewart
-
Publication number: 20100260813Abstract: A rodenticidal mixture comprising a) 0.0015 to 99.89% by weight of at least one rodenticide, b) 10?8 to 95% by weight of at least one painkiller and c) 0.01 to 99.9984% by weight of at least one biocide, where the percentages by weight are based on the total of components (a), (b) and (c), is suitable for the preparation of rodenticidal bait formulations which are employed for controlling rodent pests.Type: ApplicationFiled: September 30, 2008Publication date: October 14, 2010Applicant: BASF SEInventors: Gerhard Schnabel, Michael Ishaque, Dieter Zeller, Lars Weichel, Andrej Brejc
-
Publication number: 20100249165Abstract: This invention relates to compounds useful as PDZ domain modulators, in particular the PDZ domain of PICK1. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions.Type: ApplicationFiled: June 3, 2008Publication date: September 30, 2010Applicants: University of Copenhagen, NeuroSearch A/SInventors: Ulrik Gether, Kenneth Madsen, Thor Seneca Thorsen, Dan Peters, Tino Dyhring, Lars Christian Rønn
-
Publication number: 20100212036Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class I HDACs, which are known to participate in regulation of chromatin structure and gene expression, have generally been considered as pro-hypertrophic in their action. However, the present invention demonstrates that inhibition of certain Class I HDACs should be avoided in the treatment of cardiac hypertrophy, thereby pointing toward selective, and not global, inhibition of Class I HDACs. In particular, the present invention provides for selective inhibition of HDACs 1 and/or 2, and the avoidance of inhibition of HDAC3.Type: ApplicationFiled: September 29, 2009Publication date: August 19, 2010Inventors: Eric N. Olson, Lawrence Melvin, Rusty L. Montgomery
-
Publication number: 20100204244Abstract: Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating diabetic retinopathy or drusen formation in age-related macular degeneration. The structurally diverse agents that act on the Nrf2/ARE pathway induce the expression of enzymes and proteins that possess chemically versatile cytoprotective properties and are a defense against toxic metabolites and xenobiotics. Agents include certain electrophiles and oxidants such as a Michael Addition acceptor, diphenol, thiocarbamate, quinone, 1,2-dithiole-3-thione, butylated hydroxyanisole, flavonoid other than genistein, an isothiocyanate, 3,5-di-tert-butyl-4-hydroxytoluene, ethoxyquin, a coumarin, combinations thereof, or a pharmacologically active derivative or analog thereof.Type: ApplicationFiled: March 2, 2010Publication date: August 12, 2010Applicant: ALCON INC.Inventors: Robert A. Landers, David P. Bingaman
-
Publication number: 20100196387Abstract: In the present invention there are disclosed new derivatives of dianhydrohexite mononitrate corresponding to formula (I), tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof: as well as pharmaceutical compositions comprising these compounds and uses thereof.Type: ApplicationFiled: April 6, 2010Publication date: August 5, 2010Applicant: Lacer, S.A.Inventors: Jose Repolles Moliner, Eduardo Salas Perez-Rasilla, Francisco Pubill Coy
-
Publication number: 20100183751Abstract: Compositions comprising: vasokinetic natural coumarins or extracts containing them; anti-phosphodiesterase agents selected from 3,7-O-di-(2-hydroxyethyl)icaritin or 7-O-hydroxyethyl-icariside II and/or forskolin or extracts containing them; phytoestrogens selected from ferutinine or ferutinine-containing extracts of Ferula sp. or p-pivaloylferutinine.Type: ApplicationFiled: June 26, 2008Publication date: July 22, 2010Applicant: INDENA S.P.A.Inventor: Ezio Bombardelli
-
Publication number: 20100172964Abstract: Disclosed is a technique for allowing an active ingredient as an agent for improving or maintaining the dermal environment to reach a dermis. Specifically disclosed is a vesicle comprising the following components 1) to 3): 1) an ?,?-bis(?-N—(C10-30) acylglutamyl) lysine and/or a salt thereof; 2) ceramide and/or a derivative thereof; and 3) one or more selected from a glycerin fatty acid ester, a polyglycerin fatty acid ester and a pyroglutamic acid glycerin fatty acid ester. The acyl group in the ?,?-bis(?-N—(C10-30) acylglutamyl) lysine is preferably a lauroyl group. The ceramide or the derivative thereof is preferably ceramide type-2 or ceramide type-3. The vesicle can encapsulate an active ingredient. The vesicle can be contained in an external preparation for the skin.Type: ApplicationFiled: April 10, 2008Publication date: July 8, 2010Applicant: POLA CHEMICAL INDUSTRIES INC.Inventors: Hidetaka Akatsuka, Hitoshi Imamura, Yasuyuki Ishihara
-
Publication number: 20100168225Abstract: Compounds of Formula 5 and prodrug compounds of Formula 5 wherein G1 is H or OH; G2 is H, R?, or CO2R?; G3, G4 and G5, are each independently selected from the group consisting of: H, R?, OH, OR?, F, Cl, Br, I, NH2, NHR?,NR?2, CN, SH, SR?, SO3H, SO3R?, SO2R?, OSO3R?, and NO2; and R? is a one to four carbon alkyl group are provided. Uses of these compounds and methods of medical treatment involving these compounds for the treatment of hepatitis C are also provided.Type: ApplicationFiled: April 18, 2008Publication date: July 1, 2010Inventors: Francois Jean, Raymond Andersen
-
Publication number: 20100168224Abstract: The present invention relates to a method for controlling blood glucose level and a method for the prophylaxis or treatment of diabetes mellitus and/or its complications. The present invention further relates to an anti-diabetic formulation for controlling blood glucose level and/or for the prophylaxis or treatment of diabetes mellitus and/or its complications.Type: ApplicationFiled: December 31, 2008Publication date: July 1, 2010Applicant: Taipei Medical UniversityInventors: Yu-Chih Liang, Der-Zen Liu, Ling-Fang Hung, Pei-Jung Lin, Nai-Qi Chen, Yu-Chien Chen
-
Patent number: 7745487Abstract: This invention relates to a composition containing quercetin, vitamin B3, vitamin C, and folic acid. Also disclosed is a method of using the composition for enhancing physical or mental performance or treating various diseases or disorders.Type: GrantFiled: July 16, 2007Date of Patent: June 29, 2010Assignee: Quercegen Pharma LLCInventor: Thomas Christian Lines
-
Patent number: 7745486Abstract: This invention relates to a composition containing quercetin, vitamin B3, and vitamin C. Also disclosed is a method of using the composition for enhancing physical or mental performance or treating various diseases or disorders.Type: GrantFiled: July 16, 2007Date of Patent: June 29, 2010Assignee: Quercegen Pharma LLCInventor: Thomas Christian Lines
-
Publication number: 20100158885Abstract: Methods of and compositions for producing and using plant-based materials are provided. The methods include using biopolymers or their synthetic equivalents combined with a stable source of reactive oxygen species that when applied to or combined with a separate source of oxido-reducing enzyme or catalyst will cause the formation of an activated biopolymer with increased protein binding affinity and microbial control activities.Type: ApplicationFiled: March 1, 2010Publication date: June 24, 2010Applicant: METAACTIV, INC.Inventors: Alexander L. Huang, Gin Wu
-
Publication number: 20100152272Abstract: Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH2 are biologically active compounds; each X is independently selected from —CH2COO— (glycolic acid moiety), —CH(CH3)COO— (lactic acid moiety), —CH2CH2OCH2COO— (dioxanone moiety), —CH2CH2CH2CH2CH2COO— (caprolactone moiety), —(CH2)yCOO—, where y is 2-4 or 6-24 and —(CH2CH2O)zCH2COO—, where z is 2-24; each Y is independently selected from —COCH2O— (glycolic ester moiety), —COCH(CH3)O— (lactic ester moiety), —COCH2OCH2CH2O— (dioxanone ester moiety), —COCH2CH2CH2CH2CH2O— (caprolactone ester moiety), —CO(CH2)mO—, where m is 2-4 or 6-24 and —COCH2O(CH2CH2O)n— where n is between 2-24; R? is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.Type: ApplicationFiled: February 17, 2010Publication date: June 17, 2010Applicant: BEZWADA BIOMEDICAL, LLCInventor: Rao S. Bezwada
-
Publication number: 20100137345Abstract: The invention relates to the use of sirtuin inhibitors for reducing TNF-alpha production by cells and organisms. The invention also concerns prophylactic and therapeutic applications of sirtuin inhibitors in TNF-alpha mediated pathologies, such as various inflammatory and autoimmune disorders.Type: ApplicationFiled: May 14, 2008Publication date: June 3, 2010Applicant: Universite Libre de BruxellesInventors: Oberdan Leo, Mara Galli, Frédéric Van Gool
-
Publication number: 20100137426Abstract: Reference controls for use with pharmacogenomic testing, and methods for their identification, preparation, and use, are disclosed. The reference controls can confirm that pharmacogenomic testing correctly identifies individuals that do or do not have the mutation of interest, in both clinical trial and patient treatment settings. The reference controls can be selected to include one or more mutations to be identified, and prescreened to confirm that they bind to one or more of the primers used in the pharmacogenomic testing. The reference controls are human genomic DNA that includes certain identified polymorphisms (mutations) of interest, ideally derived from individuals, pre-selected and optionally properly consented, which have one or more of the polymorphism(s) of interest.Type: ApplicationFiled: May 1, 2009Publication date: June 3, 2010Applicant: PARAGONInventors: Michael P. Murphy, L. Scott Clark, Pamela J. Nakhle, Kenneth G. Butz
-
Publication number: 20100130599Abstract: The present disclosure is related to a method of identifying a subject with increased sensitivity to warfarin. The method includes identifying a CYP2C9*8 polymorphism in the subject, wherein the presence of said polymorphism is indicative of a patient with increased sensitivity to warfarin relative to a subject having the corresponding wild-type allele.Type: ApplicationFiled: October 2, 2009Publication date: May 27, 2010Inventors: William COTY, Larisa Cavallari
-
Publication number: 20100113460Abstract: Disclosed are compounds having the ability to inhibit cytochrome P450 2A6, 2A13, and/or 2B6 and tobacco products comprising them. Also disclosed are pharmaceutical compositions comprising them.Type: ApplicationFiled: March 20, 2008Publication date: May 6, 2010Applicant: Givaudan SAInventors: Boris Schilling, Wolf D. Woggon, Antoinette Chougnet, Thierry Granier, Georg Frater, Andreas Hanhart
-
Patent number: 7696246Abstract: The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR. Also provided are methods of making such compounds and pharmaceutical compositions, as well as critical intermediates used in their synthesis.Type: GrantFiled: June 23, 2005Date of Patent: April 13, 2010Assignee: Ligand Pharmaceuticals IncorporatedInventors: Lin Zhi, Cornelis Arjan Van Oeveren, Esther Martinborough
-
Publication number: 20100087358Abstract: The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increase receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for the NOTCH-1 mutations may be used diagnostically or as part of a treatment regimen for cancer patients.Type: ApplicationFiled: May 22, 2009Publication date: April 8, 2010Applicants: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Jon C. Aster, Stephen C. Blacklow, A. Thomas Look, Adolfo A. Ferrando, Andrew P. Weng
-
Patent number: 7683095Abstract: Compositions and methods for the treatment, reduction and/or prevention of cardiovascular diseases and disorders are described. Individuals at high risk for developing or having cardiovascular disease or disorder may be treated with an effective dose of a polymethoxyflavone including limocitrin derivatives, quercetin derivatives, naturally occurring polymethoxyflavones, tocotrienols, and mixtures of these compounds.Type: GrantFiled: May 26, 2004Date of Patent: March 23, 2010Assignees: The United States of America as represented by the Secretary of Agriculture, KGK Synergize, Inc.Inventors: Najla Guthrie, Elzbieta Maria Kurowska, John A. Manthey
-
Publication number: 20100069474Abstract: The present invention is directed to novel coumarin derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to ion channels such as potassium channelsType: ApplicationFiled: November 24, 2009Publication date: March 18, 2010Inventors: Nareshkumar F. Jain, Zhihua Sui
-
Publication number: 20100069379Abstract: The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR. Also provided are methods of making such compounds and pharmaceutical compositions, as well as critical intermediates used in their synthesis.Type: ApplicationFiled: November 13, 2009Publication date: March 18, 2010Inventors: Lin Zhi, Christopher Tegley, Barbara Pio, Corneils Arjan Van Oeveren, Mehrnouch Motamedi, Esther Martinborough, Robert Higuchi, Lawrence G. Hamann
-
Publication number: 20100048604Abstract: The present invention relates to compounds useful for detecting the activity of human aldoketoreductase 1Cs, compounds useful for competitively inhibiting human aldoketoreductase 1Cs and compounds useful for treating human aldoketoreductase 1C-related cancers, as well as pharmaceutical compositions and methods of manufacture thereof.Type: ApplicationFiled: August 19, 2005Publication date: February 25, 2010Inventors: Dominic J. Yee, Vojtech Balsanek, Dalibor Sames
-
Patent number: 7666902Abstract: The subject invention provides anticoagulant compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R3, n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The invention further comprises pharmaceutical compositions comprising the compounds and salts of the invention, as well as methods of using the compounds, salts, and compositions of the invention.Type: GrantFiled: July 16, 2007Date of Patent: February 23, 2010Assignee: ARYx Therapeutics, Inc.Inventors: Pascal Druzgala, Cyrus Becker
-
Publication number: 20100034878Abstract: Medications which are derived by combining one or more doses of the agonist, vitamin K, with doses of one or more selected vitamin K antagonists such as the R-isomer of warfarin, the R-isomer of phenprocoumon, or the racemic phenprocoumon are useful in anticoagulant therapy. These products are designed to minimize or circumvent the detrimental impact of newly identified genetic-based variables that currently significantly complicate the therapeutic response of individual patients to anticoagulation therapy.Type: ApplicationFiled: December 18, 2007Publication date: February 11, 2010Inventors: Henry I. Bussey, Marie B. Walker
-
Publication number: 20100029580Abstract: The present invention relates to the constitutive activity of the Hedgehog pathway in non-small cell lung carcinoma (NSCLC). A method for diagnosing NSCLC by detecting the level of a component of the Hedgehog pathway is provided, as is a method for identifying subjects that will respond positively to treatment with a Hedgehog pathway antagonist. Methods for treating subjects with cancer or cancers resistant to Hedgehog pathway antagonists are also provided.Type: ApplicationFiled: April 12, 2006Publication date: February 4, 2010Inventors: David J. Robbins, Ziqiang Yuan, John A. Goetz
-
Publication number: 20100022635Abstract: The disclosure provides novel dosing regimens for Hsp90 inhibitors for use in the treatment or prevention of a neurodegenerative disorder, an autoimmune disorder, or cancer. The methods involve administering one or more doses of a therapeutically effective amount of at least one Hsp90 inhibitor to a subject in need thereof such that no more than a single dose is administered within a period of about 7 days.Type: ApplicationFiled: July 28, 2009Publication date: January 28, 2010Applicant: University of KansasInventor: Roger A. Rajewski
-
Publication number: 20100009927Abstract: The present invention relates in part to nettle extracts that are useful for treating or preventing seasonal allergies, allergic rhinitis, and other inflammatory conditions.Type: ApplicationFiled: July 14, 2009Publication date: January 14, 2010Applicant: HerbalScience Group LLCInventors: Randall S. Alberte, William P. Roschek, JR., Dan Li
-
Patent number: 7642364Abstract: The invention relates to pesticide and bactericide, specifically to the benzopyrone compounds and its preparation method and use thereof. The benzopyrone compounds of the invention having general formula (I): The present invention, having good pesticide activity and broad bactericide activity, applied for controlling various pests in plants such as army worm, diamond backmoth and aphid, carmine spider mite, two-spotted spider mite, ladybeetle, mites and mosquito larvae. Various disease in plants can be controlled by the invention and that of grape downy mildew, rice sheath and culm blight, rice blast, tomato early blight, tomato late blight, wheat leaf rust, wheat leaf blotch, wheat powdery mildew, cucumber powdery mildew, cucumber downy mildew, cucumber grey mold and so on.Type: GrantFiled: November 4, 2004Date of Patent: January 5, 2010Assignee: Shenyang Research Institute of Chemical IndustryInventors: Changling Liu, Aiying Guan, Hong Zhang, Mingxing Zhang, Zhengming Li, Miao Li, Lin Li, Zhinian Li, Chunqing Hou
-
Patent number: 7638554Abstract: Compounds useful as chemotherapeutic, chemopreventive, and antiangiogenic agents are provided. The compounds are flavanoids, including flavanones, flavanols, and chalcones. The compounds have the structure of formula (I) wherein R1 through R3 and R5 through R11 are defined herein, and ?, ? and ? are optional bonds, providing that when ? is absent, ? is present, and when ? is absent, ? is present. When ? is present, preferred R4 moieties are selected from O, S, NH and CH2, and when ? is absent, preferred R4 groups are selected from OH, SH, NH2 and CH3. When ? is present, the preferred R5 substituent is O, while when ? is absent, the preferred R5 substituent is OH. Pharmaceutical compositions are provided as well, as are methods of synthesis and use.Type: GrantFiled: April 14, 2006Date of Patent: December 29, 2009Assignee: SRI InternationalInventors: Nahid Waleh, Nurulain T. Zaveri
-
Publication number: 20090318546Abstract: A compound of formula (I) wherein R1, R2, R3, R4, R5, and ring A are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.Type: ApplicationFiled: April 10, 2007Publication date: December 24, 2009Applicant: NOVARTIS AGInventors: Rolf Baenteli, Nigel Graham Cooke, Sven Weiler, Frederic Zecri
-
Publication number: 20090285797Abstract: The invention relates to methods and compositions for regulating nicotine metabolism. Also provided are methods for screening and assessing substances for regulating nicotine metabolism. Methods are provided for assessing nicotine metabolism.Type: ApplicationFiled: September 25, 2008Publication date: November 19, 2009Applicant: Nicogen Inc.Inventors: Edward M. Sellers, Rachel F. Tyndale
-
Publication number: 20090275650Abstract: Compounds of Formula I: wherein R1, R2, M, Q and n are as defined herein, are useful as antiproliferative agents including, for example, as anticancer agents.Type: ApplicationFiled: June 2, 2006Publication date: November 5, 2009Applicant: TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: M.V. Ramana Reddy, E. Premkumar Reddy
-
Publication number: 20090274737Abstract: An implant for a human or animal body, comprising a surface having reduced thrombogenic properties, whose surface has a wetting angle of ?, where ??80°. Also disclosed is a method for producing an implant and the use an implant to reduce the dose or concentration in administration of a concomitant systemic medication with one or more anticoagulant active ingredients before, during or after implantation of the implant in a human or animal body.Type: ApplicationFiled: May 4, 2009Publication date: November 5, 2009Applicant: BIOTRONIK VI PATENT AGInventor: Alexander Borck
-
Publication number: 20090270332Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: March 13, 2009Publication date: October 29, 2009Applicant: CELERA CORPORATIONInventors: Lance BARE, James J. DEVLIN, Frits R. ROSENDAAL, Pieter H. REITSMA, Irene D. BEZEMER
-
Patent number: 7589122Abstract: Soybean volatile compounds, soybean aphid-induced volatile compounds and soybean aphid sex pheromones are semiochemicals of the invention used to suppress soybean aphid population. Methyl salicylate is an embodiment of a soybean aphid-induced volatile compound useful in the invention. Benzaldehyde is an embodiment of a soybean host plant volatile compound useful in the invention. Also useful as sex pheromones are nepetalactol and nepetalactone. The compounds may be blended in a preferred embodiment.Type: GrantFiled: May 6, 2005Date of Patent: September 15, 2009Assignee: MSTRS Technologies, Inc.Inventors: Junwei Zhu, Thomas Baker
-
Patent number: 7585893Abstract: The present invention relates to the use of compounds such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) for the treatment of cancer, wherein the compounds are administered gastrointestinally, preferably orally. More particularly, the invention is concerned with the use of such compounds, wherein the compound is delivered to the site of action in the patient to be treated in two or more doses.Type: GrantFiled: April 28, 2005Date of Patent: September 8, 2009Assignee: Cancer Research Technology LimitedInventors: Bruce Charles Baguley, Lai-Ming Ching, Philip Kestell, Liangli Zhao
-
Publication number: 20090197945Abstract: Reference controls for use with pharmacogenomic testing, and methods for their identification, preparation, and use, are disclosed. The reference controls can confirm that pharmacogenomic testing correctly identifies individuals that do or do not have the mutation of interest, in both clinical trial and patient treatment settings. The reference controls can be selected to include one or more mutations to be identified, and prescreened to confirm that they bind to one or more of the primers used in the pharmacogenomic testing. The reference controls are human genomic DNA that includes certain identified polymorphisms (mutations) of interest, ideally derived from individuals, pre-selected and optionally properly consented, which have one or more of the polymorphism(s) of interest.Type: ApplicationFiled: January 29, 2007Publication date: August 6, 2009Inventors: Michael P. Murphy, Scott L. Clark, Pamela J. Nakhle, Kenneth G. Butz
-
Publication number: 20090170930Abstract: A method for promoting differentiation of clonogenic neural stem cells (NSCs), comprising administering to a patient in the need of such promoting a coumarin compound represented by formula I or by formula II. The representative coumarin compounds include 7-hydroxycoumarin, daphnoretin, scopoletin, edgeworin, aesculetin and esculetin-6-?-D-glucopyranoside. The coumarin compounds showed significant activity of directing the differentiation of NSCs in pharmacological test and thereof could be used to prepare drugs to direct NSCs differentiated to oligodendrocyte progenitor cells (OPCs) for the treatment of demyelinating diseases or spinal cord injury. The drug could be a pure coumarin compound or a pharmaceutical composition comprising a therapeutical dose of a coumarin compound as active ingredients and a pharmaceutically-acceptable carrier. The content of the active ingredients in the pharmaceutical composition is between 0.1% and 99.5% by weight.Type: ApplicationFiled: March 9, 2009Publication date: July 2, 2009Applicant: THE SECOND MILITARY MEDICAL UNIVERSITYInventors: Cheng HE, Weidong ZHANG, Xiaohui XU, Wei ZHANG, Juan SU, Chuan ZHANG
-
Publication number: 20090169560Abstract: In the present invention there are disclosed new derivatives of dianhydrohexite mononitrate corresponding to formula (I), tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof: as well as pharmaceutical compositions comprising these compounds and uses thereof.Type: ApplicationFiled: March 9, 2009Publication date: July 2, 2009Applicant: LACER S.A.Inventors: Jose Repolles Moliner, Eduardo Salas Perez-Rasilla, Francisco Pubill Coy
-
Patent number: 7553872Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: February 13, 2006Date of Patent: June 30, 2009Assignee: Emisphere Technologies, Inc.Inventors: Donald J. Sarubbi, Evgueni Barantsevitch